Deutsche Bank (DE:DBKGn) analyst Falko Friedrichs maintained a Buy rating on Qiagen (NYSE:QGEN) NV on Monday, setting a price target of $68, which is approximately 44.25% above the present share price of $47.14.
Friedrichs expects Qiagen NV to post earnings per share (EPS) of $0.57 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Qiagen, with an average price target of $59.41.
The analysts price targets range from a high of $68 to a low of $54.42.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $567.21 million and a net profit of $170.19 million. The company's market cap is $10.77 billion.
According to TipRanks.com, Deutsche Bank analyst Falko Friedrichs is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.1% and a 59.41% success rate.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.